2024 Virtual Grand Rounds
2024 Virtual Grand Rounds Session 10: September 11, 2024 - Chronic Spontaneous Urticaria: Looking Ahead for Novel Therapies
About
Fall Clinical Virtual Grand Rounds consist of regularly scheduled CME sessions on a variety of dermatological diseases, delivered by the top experts in dermatology. Please join us for this week's session:
Wednesday, September 11, 2024
8 PM ET / 5 PM PT
Chronic Spontaneous Urticaria: Looking Ahead for Novel Therapies
This activity is supported by an educational grant from Novartis Pharmaceuticals Corporation.
Availability
In order to ensure educational material is relevant, educational materials will expire after a certain time period. This course will be available for the following dates:
September 12, 2024
September 12, 2025
Learning Objectives
At the completion of this activity, participants should be better able to:
Describe strategies to diagnose patients with CSU
Describe the complex biology of CSU and how emerging therapies target the disease pathway
Overview the efficacy and safety of new and emerging biologics for the management of CSU
Describe when to choose a biologic for the management of CSU
Intended Audience
This activity has been designed for dermatologists, dermatology physician assistants, dermatology nurse practitioners, and other providers involved in the care of patients.
Faculty
Dawn Merritt, DO
Dermatology Residency Program Director
OhioHealth Riverside Hospital
Columbus, OH
Kristin Sokol, MD
Schreiber Allergy
Rockville, Maryland
Linda Stein Gold, MD
Director Clinical Research
Henry Ford Health System
Detroit, MI
Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Institute for Continuing Healthcare Education and CMEsquared. The Institute is accredited by the ACCME to provide continuing medical education for physicians.
Credit Designation Statement
The Institute for Continuing Healthcare Education designates this live and enduring activity for a maximum of 1 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosures & Disclaimers
Disclosures are as follows:
Consultant: Abbvie, Arcutis, BMS, Dermavant, Lilly, Novartis, UCB
Speaker's Bureau or Honoraria: Abbvie, Amgen, BMS, Dermavent, LEO, Lilly, Pfizer
No relevant financial relationships with any Ineligible Company in the past 24 months.
Grant/Research Support: Arcutis, BMS, Incyte, Dermavant, Galderma, Lilly, AbbVie
Consultant: Arcutis, BMS, Incyte, Dermavant, Galderma, Lilly, AbbVie
Speakers’ Bureau or Honoraria: Leo, AbbVie, Almirall, Galderma, Pfizer, Sanofi, Regeneron
The Institute discloses that all relevant conflicts have been satisfactorily mitigated.